BMPR2突变携带者肺动脉高压筛查研究
本研究对55例无症状BMPR2突变携带者进行基线及每年筛查,基线右心导管检出2例轻度PAH(3.6%)和12例运动性肺高血压(21.8%);长期随访(118.8患者年)新增3例PAH,年发病率为2.3%(男性0.99%/年,女性3.5%/年)。所有PAH患者在末次随访时口服治疗均维持低风险状态。
要点
- 无症状BMPR2突变携带者PAH年发病率为2.3%,女性高于男性。
- 基线右心导管可检出轻度PAH及运动性肺高血压。
- 多模态筛查结合定期随访有助于早期发现PAH。
核心结论
- 无症状BMPR2突变携带者发生PAH的风险显著,需重视早期筛查与随访。
研究设计与样本
- DELPHI-2研究(NCT01600898)纳入55例无症状BMPR2突变携带者,基线及每年筛查至少2年。
主要发现
- 基线右心导管检出2例轻度PAH(3.6%)和12例运动性肺高血压(21.8%)。
- 长期随访118.8患者年新增3例PAH,年发病率为2.3%(男性0.99%/年,女性3.5%/年)。
- 所有PAH患者在末次随访时口服治疗均维持低风险状态。
关键数值与推荐
- 指南基于专家共识推荐对无症状BMPR2突变携带者每年进行筛查超声心动图。
- 年度筛查包括临床评估、心电图、肺功能、6分钟步行距离、心肺运动试验、胸片、超声心动图及BNP或NT-proBNP。
- 根据预设标准行右心导管检查,基线时可选静息和运动右心导管。
临床怎么用
- 对无症状BMPR2突变携带者应进行年度多模态筛查并结合右心导管评估。
- 筛查中需关注运动性肺高血压及女性携带者的较高发病风险。
局限性
- 样本量较小(55例),需国际多中心研究验证 refined 多模态筛查方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heritable pulmonary arterial hypertension (PAH) is most commonly due to heterozygous mutations of the BMPR2 gene. Based on expert consensus, guidelines recommend annual screening echocardiography in asymptomatic BMPR2 mutation carriers. The main objectives of this study were to evaluate the characteristics of asymptomatic BMPR2 mutation carriers, assess their risk of occurrence of PAH and detect PAH at an early stage in this high-risk population. METHODS: Asymptomatic BMPR2 mutation carriers underwent screening at baseline and annually for a minimum of 2 years (DELPHI-2 study; ClinicalTrials.gov: NCT01600898). Annual screening included clinical assessment, ECG, pulmonary function tests, 6-min walk distance, cardiopulmonary exercise testing, chest radiography, echocardiography and brain natriuretic peptide (BNP) or N-terminal (NT)-proBNP level. Right heart catheterisation (RHC) was performed based on predefined criteria. An optional RHC at rest and exercise was proposed at baseline. RESULTS: 55 subjects (26 males; median age 37 years) were included. At baseline, no PAH was suspected based on echocardiography and NT-proBNP levels. All subjects accepted RHC at inclusion, which identified two mild PAH cases (3.6%) and 12 subjects with exercise pulmonary hypertension (21.8%). At long-term follow-up (118.8 patient-years of follow-up), three additional cases were diagnosed, yielding a PAH incidence of 2.3% per year (0.99% per year in males and 3.5% per year in females). All PAH cases remained at low-risk status on oral therapy at last follow-up. CONCLUSIONS: Asymptomatic BMPR2 mutation carriers have a significant risk of developing incident PAH. International multicentre studies are needed to confirm that refined multimodal screening programmes with regular follow-up allow early detection of PAH.
引用
- Montani D, Girerd B, Jaïs X, et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J. 2021. PMID: 33380512. doi:10.1183/13993003.04229-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。